The wealth of preclinical and clinical data implicating both central CRH-containing circuits and HPA axis dysfunction in PTSD supports testing of candidate medications that modulate this system, particularly considering the dearth of medications demonstrated to be efficacious for PTSD. The gene discussed is CRH; the disease is post-traumatic stress disorder.